Business
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Franci...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, Jan. 5, 2017\n\n\n\nCALGARY, Jan. 5, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\", or the \"Company\") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.\n\nPresentation Details:\n\nDate: January 9th Time: 2:00pm PT Duration: 30 minutesLocation: Room 3 (Ballroom Level) at the Hilton San Francisco Union Square \n\nMr. McCaffrey's presentation will be available on the Company website on the Media/Events page immediately prior to the scheduled presentation time. \n\nTo schedule a meeting with senior management in San Francisco during the event, please contact Investor Relations.\n\nAbout Resverlogix\n\nResverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). \n\nResverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). \n\nFor further information please visit www.resverlogix.com. \...